delcath.com - DCTH Company Value to Revenue

Public company logo of Delcath Systems Inc (DCTH)

High regulatory barriers and medtech patents protect the position of Delcath Systems, Inc. (DCTH). The EV/Sales multiple history visualizes the market valuation of the business relative to revenue, where the 5160.24 indicator reflects the asset's status. Delcath Systems, Inc. (DCTH) aims for dominance in liver metastasis therapy via the Hepzato system, while strict REMS programs make entry for new players virtually impossible.

DCTH Delcath Systems Inc Company Value to Revenue (11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Delcath (DCTH)

Initial company analysis:DCTH (Delcath Systems)
Product sample of Delcath Systems Inc

Business vulnerability to market shocks often depends on the efficiency of capitalizing current earnings. The reliability of specialized medical logistics at Delcath Systems, Inc. (DCTH) ensures supply stability, creating the necessary operational foundation. The EV/Sales metric relates the total enterprise value, including debt, to annual revenue. By analyzing the valuation dynamics of Delcath Systems, Inc. (DCTH) via EV/Sales, an investor determines the extent of the premium paid for the asset. Comparing current values with historical trends allows for the identification of fair value points.

Direct competitors

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio